/
DFTX
$46.14+$1.75 (+3.94%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$6.1B
133M shares
52-week range
$14.62 – $49.20
91% from low
Sector
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Exchange
NASDAQ
CS
Change+$30.76
Definium Therapeutics, Inc. Common Shares
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
www.definiumtx.com- Employees
- 106
- IPO / List date
- Mar 3, 2020
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds DFTX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in DFTX as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded DFTX yet.
